Early-Stage HER2-Positive Disease and Neoadjuvant Considerations

Dr. Kruse addresses the complexity introduced by simultaneous release of DESTINY-Breast05 and -11 data, requiring contextualization of both neoadjuvant and adjuvant approaches. DESTINY-Breast05 focused on a higher-risk population with residual disease after neoadjuvant therapy, specifically patients who were initially inoperable due to extensive breast or lymph node involvement or had residual disease in lymph nodes. This differs from the broader KATHERINE study population, where patients with minimal residual disease performed well with trastuzumab emtansine (T-DM1).

The adjuvant setting comparison shows T-DXd achieving superior invasive disease-free survival compared to T-DM1 by approximately 9%, but toxicity considerations become paramount in curative-intent treatment. ILD occurs in about 10% of patients with grade 5 events reported, raising concerns about life-threatening toxicity in potentially curable patients. Dr. Kruse emphasizes selective patient identification for T-DXd based on risk stratification among residual disease patients.

DESTINY-Breast11 represents the first randomized neoadjuvant study incorporating T-DXd, enrolling high-risk patients (T3 or higher, node-positive, inflammatory breast cancer) randomized between standard anthracycline-taxane approaches versus T-DXd followed by trastuzumab-pertuzumab. The intervention demonstrated 11.2% improvement in pathologic complete response (pCR) rates (67% versus 56%), with benefits across hormone receptor subgroups. Hormone receptor-negative patients achieved 83% pCR rates, whereas hormone receptor-positive patients reached 61% pCR rates. Interestingly, pneumonitis rates were identical between T-DXd and control arms, suggesting surveillance bias in detecting this toxicity.